Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 1;39(31):3419-3422.
doi: 10.1200/JCO.21.01414. Epub 2021 Jul 26.

Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Deborah M Stephens  1
Affiliations
Editorial

Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Deborah M Stephens. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Deborah M. StephensHonoraria: GenentechConsulting or Advisory Role: Pharmacyclics/Janssen, Karyopharm Therapeutics, BeiGene, Innate Pharma, Epizyme, TG Therapeutics, Adaptive Biotechnologies, AstraZenecaResearch Funding: Acerta Pharma, Gilead Sciences, Karyopharm Therapeutics, Verastem, Juno Therapeutics, ArQule, MingSightNo other potential conflicts of interest were reported.

Comment on

References

    1. Byrd JC, Hillmen P, O'Brien S, et al. : Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133:2031-2042, 2019 - PMC - PubMed
    1. Burger JA, Barr PM, Robak T, et al. : Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:787-798, 2020 - PMC - PubMed
    1. Shanafelt TD, Wang XV, Kay NE, et al. : Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381:432-443, 2019 - PMC - PubMed
    1. Sharman JP, Egyed M, Jurczak W, et al. : Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet 395:1278-1291, 2020 - PMC - PubMed
    1. Ghia P, Pluta A, Wach M, et al. : ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 38:2849-2861, 2020 - PubMed

MeSH terms

Substances